Merck & Co (MRK)
$126.45
0.60 (0.48%)
MRK Stock Quote Delayed 30 Minutes
3 Crash-Proof Medical Stocks to Keep Your Portfolio’s Pulse
The recent rally won't last forever, but investors wanting to jump in can still do so -- and protect themselves -- by getting into these health-related equities.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
320.09B
PE Ratio
140.50
EPS
0.9
Volume (Avg. Vol.)
6.79M
Day's Range
$124.91 - $126.60
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
3 Health Care Plays With Healthy Dividends
These long-term picks fit the bill if you agree this sector's future is sound. Demographic trends alone make for a compelling argument.
The Tax Company Cometh on Strong
H&R Block has had a strong run-up to tax season, but there are still plenty of reasons to buy -- especially for income investors.
The Little Guys Are Pharma’s New Stars
Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules.
Are Pharma’s ‘Good Old Days’ Gone Forever?
You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry.
Novartis Cutting 2,000 Jobs – So Much for Healthy Healthcare Stocks!
Novartis NYSE:NVS is cutting nearly 2,000 jobs in the United States. The reason? Patent expiration for its blockbuster blood pressure drug Diovan.
Merck Is Shopping for Smarts In Hep C
The pharma giant says it's determined to be the leader in treatments for the disease -- a market that is expected to hit $20 billion by 2020.
8 Pharma Stocks in Good Health
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.
Top 10 Dow Dividend Stocks
Lock in long-term income during good times and bad with these creme de la creme income generators.
Why Eli Lilly Could Be a Lottery Stock Pick
If Eli Lilly is successful in delaying the progression of Alzheimer’s disease with its experimental drug, it could make Lipitor look like a mid-sized product. The odds?
Value Investors Should Feel Like a ‘Kid in a Candy Store’
A glut of top-rate companies are available for a song right now. Here's what value investors should be grinning about.
3 Dividend Stocks to Ride the Rally
Investors who are nervous about diving back into the stock market should just dip their toes in the water. Here are three reliable dividend stocks to consider.
Top 6 Stocks for December
A focus on earnings strength and dividend increases place energy and retail at the top of this month’s list of stocks investors should be buying.
Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term
Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.
Pfizer Pushes to Keep Lipitor Profits Flowing
Efforts to preserve the lucrative cholesterol-drug's franchise have sparked an antitrust suit. But competition is inevitable.
10 Companies Increasing Dividends
Merck and ADP top the list of stocks increasing dividends this week. See eight other companies making shareholders smile.
Hepatitis C Drug Progress Puts Several Companies on Acquisition Watch
With their hepatitis C drugs showing promise in trials, these drug makers have become attractive targets for bigger pharma players.
9 Recession-Proof Biotech Stocks To Cure What Ails You
Health care stocks stay firm during a down economy and investors should consider up-and-coming biotech stocks like Alexion, Alkermes, Biogen and Cepheid.
Top 10 Dow Dividend Stocks
These 10 Dow Jones components are not just strong companies -- they are some of the best dividend-yielding stocks you can buy.
Should You Buy the Dow — Pfizer
Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.
Big Pharma Might Already Have Sights on Abbott Spinoff
Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.
